ClinicalTrials.gg
RecruitingNCT05102240Updated Feb 20, 2026

Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer

An observational study in Cervix Cancer, sponsored by Tata Memorial Hospital. Recruiting at 1 site in India. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Tata Memorial Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1,800
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital — 9 open to participants now, 9 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Tata Memorial Hospital.

Planned enrollment
Largest of 10
1,800 · median 325
Started
2022
the only one that year
Observational
10 of 27
6 open now
Registered
20th of 27
by date

Among the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, this one has the largest planned enrollment of the 10 observational ones that give a count, is the only one that started in 2022, is one of 10 observational ones, and was the 20th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

9 of the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital are open now, in 3 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, or all of them as a file.
02

Study summary

Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability

Hypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.

Read the detailed description

For Aim 1. Automatic delineation of complex tumour targets for cervical cancer for the Gross Tumour Volume (GTV) at baseline and at brachytherapy and High Risk Clinical Target Volume(CTV) at baseline and brachytherapy will be done on MRI.

Following structures will be processed for automation on CT

  1. Low Risk Clinical Target Volume (Low Risk CTV)
  2. GTV: Nodal
  3. Elective Nodal Pelvic Target Volume
  4. Elective Nodal Pelvic and Paraaortic Volume
  5. Rectum
  6. Bladder
  7. Sigmoid
  8. Bowel
  9. Bone Marrow

For Aim 2. The Investigator intend to employ machine learning for developing more robust normal tissue toxicity prediction models. Further advanced techniques like texture analysis of radiation dose maps and follow up tissue density will also be performed to develop predictive models of toxicity. By using our patient datasets, Investigator want to create a library of proton beam plans with the proton planning systems that will be available in department of radiation oncology and using the developed normal tissue complication plots available the information of achievable doses through protons can help in identifying patients who will benefit from proton therapy.

For Aim 3. Within this project Investigator intend to integrate staging, pathology and quantitative imaging texture features for response prediction and identification of "high risk cohort" in cervix cancer. Images and clinical data from patients that have MRI at baseline will be included The texture features can be used to categorise "good" and "poor responders" after chemoradiation. For the same cohort of patients the Investigator also have tissue available including results of additional biomarkers (like AKT,LICAM, PDL1,CD4 and CD8). The Investigator intend to first correlate difference in texture features and see if there is a pattern of different molecular features. In the second step imaging and molecular features could be integrated for developing" risk prediction models". GTV and HRCTV delineated on 150 data sets at baseline and brachytherapy within Aim 1 will be utilised to categorise responders and non-responders and validate another 150 patient data sets.

03

Conditions studied

  • Cervix Cancer

Keywords

  • Advanced Radiation Technology
  • Quantitative Imaging
  • Molecular Biology
  • Machine Learning
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cervical cancer patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer at our institute with access to MRI/CT images at time of diagnosis and brachytherapy, undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Aim 1 and Aim 3:

  • Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI/CT images at the time of diagnosis and brachytherapy For Aim 2
  • Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.

Exclusion criteria

Exclusion Criteria:

  1. Lack of disease or toxicity outcomes.
  2. Lack of images in the hospital database.
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1,800 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Generation of software for automated target delineation for cervix cancer

    1\. To develop and validate automated platforms for target delineation and planning for cervix cancer in time efficient manner through a. Machine learning based detection of abnormal cancerous tissues in multimodality medical diagnostic images. b . To train machine base systems for automated planning of external radiation and brachytherapy for gynaecological cancers.

    Time frame: 3 years

  2. Development and validation of Normal Tissue Complication Plots

    2\. To use existing databases and radiation dose maps, imaging texture features and adverse events data for machine learning to develop "normal tissue complication plots "and to identify cervix cancer patient subgroups that may benefit from advanced radiation techniques (like proton treatment)

    Time frame: 3 years

  3. Identify "high risk patient population" that may benefit from intensification of treatment in future

    3\. To use advanced image texture analysis within ongoing institutional and collaborative clinical trials to identify "high risk patient population" that may benefit from intensification of treatment in future

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
  • Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre
    Navi Mumbai, Maharashtra 410210, India
    Recruiting
    • Dr Supriya Chopra, MD · Contactschopra@actrec.gov.in · 91-22-27405000
    • Supriya Chopra, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Jun 2026, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2021
First posted
Nov 1, 2021
StartActual
Feb 24, 2022
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05102240
Lead sponsor
Tata Memorial Hospital
Collaborators
Bhabha Atomic Research Centre, Erasmus Medical Center
Responsible party
Supriya Sastri (chopra) (Professor, Radiation Oncology, Tata Memorial Hospital) — Principal investigator
First posted
Nov 1, 2021
Start date
Feb 24, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Feb 20, 2026

Study contacts

Supriya Sastri (nee Chopra), MD
Contact
supriyasastri@gmail.com
02227405000 ext. 5113
Supriya Sastri (nee Chopra), MD
Contact
schopra@actrec.gov.in
02227405000 ext. 5113
Supriya Sastri (nee Chopra), MD
principal investigator · Tata Memorial Centre, The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion